Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001334095 | SCV001526839 | uncertain significance | Combined oxidative phosphorylation defect type 8 | 2018-09-14 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV002054316 | SCV002351023 | likely benign | not provided | 2022-06-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004601124 | SCV005099513 | uncertain significance | Inborn genetic diseases | 2024-06-11 | criteria provided, single submitter | clinical testing | The c.533C>T (p.A178V) alteration is located in exon 3 (coding exon 3) of the AARS2 gene. This alteration results from a C to T substitution at nucleotide position 533, causing the alanine (A) at amino acid position 178 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |